BioCentury
ARTICLE | Emerging Company Profile

Exploiting alpha-GAL

How Agalimmune’s alpha-GAL can get endogenous antibodies to destroy solid tumors

November 4, 2016 6:44 PM UTC

By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases.

The newco’s Alphaject therapies are small molecule analogs of glycolipids expressing the galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-GAL) epitope. ...